POM-V Prescription Required Companion Animal

Kelapril 5 mg, Film-coated Tablets for Dogs and Cats

Active ingredient: Benazepril Hydrochloride

Form

Tablet

Species

Cats Dogs

Manufacturer

VetViva Richter GmbH

VMD MA No.

57446/3003

What it's used for

Cats: Reduction of proteinuria associated with chronic kidney disease.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Benazepril Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Kelapril 5 mg, Film-coated Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cats:
Reduction of proteinuria associated with chronic kidney disease.

The veterinary medicinal product should be given orally once daily, with or without
food. The duration of treatment is unlimited.
Dogs:
The veterinary medicinal product should be administered orally at a minimum dose of
0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily,
according to the following table:
“Product name” 5 mg
(to be completed nationally )
Weight of
dog (kg)
Standard doseDouble dose
> 5 – 100.5 tablet1 tablet> 10 – 201 tablet2 tablets
The dose may be doubled, still administered once daily, to a minimum dose of 0.5
mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary
surgeon.
AN: 02967/2024Page 5 of 8
Cats:
The veterinary medicinal product should be administered orally at a minimum dose of
0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight once daily according
to the following table:
Weight of cat
(kg)
“Product name” 5 mg
(to be completed
nationally )
2.5 - 50.5 tablet> 5 - 101 tablet

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal
failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
Do not use in pregnancy or lactation (see section 3.7).

Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Vomiting;
Fatigue.
Very rare
(<1 animal / 10,000 animals
treated,
including isolated reports):
Elevated creatinine
;
Incoordination.
In dogs with chronic kidney disease, the product may increase plasma creatinine
concentrations at the start of therapy. A moderate increase in plasma creatinine
concentrations following administration of ACE inhibitors is compatible with the
reduction in glomerular hypertension induced by these agents, and is therefore not
necessarily a reason to stop therapy in the absence of other signs.
Cats:
Rare
(1 to 10 animals / 10,000
animals treated):
Diarrhoea, Vomiting;
Anorexia, Dehydration, Lethargy.
Very rare
(<1 animal / 10,000 animals
treated,
including isolated reports):
Elevated creatinine
;
Increased appetite, Weight gain.
In cats with chronic kidney disease, the product may increase plasma creatinine
concentrations at the start of therapy. A moderate increase in plasma creatinine
concentrations following administration of ACE inhibitors is compatible with the
reduction in glomerular hypertension induced by these agents, and is therefore not
necessarily a reason to stop therapy in the absence of other signs.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
No evidence of renal toxicity of the veterinary medicinal product has been observed
(in dogs or cats) during clinical trials, however, as is routine in cases of chronic
kidney disease, it is recommended to monitor plasma creatinine, urea and
erythrocyte counts during therapy.
The efficacy and safety of the veterinary medicinal product has not been established
in dogs and cats below 2.5 kg body weight.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
People with known hypersensitivity to benazepril hydrochloride should avoid contact
with the veterinary medicinal product.
Pregnant women should take special care to avoid accidental oral exposure because
angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn
child during pregnancy in humans.
To avoid accidental ingestion, particularly by a child, unused part-tablets should be
returned to the open blister space and inserted back into the carton.
In case of accidental oral ingestion, seek medical advice immediately and show the
label or the package leaflet to the physician.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
AN: 02967/2024Page 3 of 8

In dogs with congestive heart failure, the veterinary medicinal product has been given
in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary
medicinal products without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal
function. The combination of the veterinary medicinal product and other anti-
hypertensive agents (e.g. calcium channel blockers, or diuretics),
anaesthetics or sedatives may lead to additive hypotensive effects. Therefore,
concurrent use of NSAIDs or other medications with a hypotensive effect should be
considered with care. Renal function and signs of hypotension (lethargy, weakness
etc.) should be monitored closely and treated as necessary.
Interactions with potassium preserving diuretics like spironolactone, triamterene or
amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels
when using the veterinary medicinal product in combination with a potassium sparing
diuretic because of the risk of hyperkalaemia.

Store below 25°C in the original package.
Store in a dry place.
Each time an unused half tablet is stored, it should be returned to the open blister
space inserted back into the cardboard box and used at the next administration.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.